Arbutus Biopharma Corporation (NASDAQ:ABUS) is expected to report second quarter earnings results, before market open, on Friday 7th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.24 per share from revenue of $ 1.74 million.
Looking ahead, the full year loss are expected at $ 0.91 per share on the revenues of $ 7.09 million.
Previous Quarter Performance
Arbutus Biopharma Corporation announced loss for the first quarter of $ 0.25 per share, from the revenue of $ 1.49 million. The quarterly earnings escalated 41.67 percent while revenues compared with the same quarter last year.
Wall street analysts are predicting, ABUS to report 1Q20 loss of $ 0.39 per share from revenue of $ 0.22 million. The bottom line results beat street analysts by $ 0.14 or 35.90 percent.
Historical Earnings Performance wpDataTable with provided ID not found!
Click Here For More Historical Earnings Of Arbutus Biopharma Corporation
Stock Performance
The company has a market capital of $ 307.57 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ABUS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Arbutus Biopharma Corporation will be hosting a conference call at 8:45 AM eastern time on 7th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.arbutusbio.com
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease.
